NCT04646356View on ClinicalTrials.gov

Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT)

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

October 20, 2020

Primary Completion Date

January 15, 2024

Study Completion Date

October 21, 2024

Conditions
Hereditary Hemorrhagic TelangiectasiaEpistaxis Nosebleed
Interventions
DRUG

Tacrolimus capsule (low-dose)

low-dose Tacrolimus will be given for 6 months followed by a washout period for 6 months

Trial Locations (1)

M5B1W8

St. Michael's Hospital, Toronto

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Unity Health Toronto

OTHER

NCT04646356 - Tacrolimus Trial for Hereditary Hemorrhagic Telangiectasia (HHT) | Biotech Hunter | Biotech Hunter